# Czech Pharmaco-epidemiological Study on Disease Modifying Drugs

> **NCT05762003** · — · COMPLETED · sponsor: **IMPULS Endowment Fund** · enrollment: 17478 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab

## Key facts

- **NCT ID:** NCT05762003
- **Lead sponsor:** IMPULS Endowment Fund
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 17478 (ACTUAL)
- **Last updated:** 2023-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05762003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05762003, "Czech Pharmaco-epidemiological Study on Disease Modifying Drugs". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05762003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*